ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1945

Early Prediction of Long-Term Renal Outcomes in Lupus Nephritis Using Hazard Index Equations

Farah Tamirou1, Meggan Mackay2, Maria Dall'Era3, Joanna Fishbein4, Kenneth C. Kalunian5, Brad H. Rovin6 and Frédéric A. Houssiau7, 1Rheumatology Department, Cliniques universitaires Saint-Luc, Brussels, Belgium, 2The Feinstein Institute for Medical Research, Manhasset, NY, 3University of California, San Francisco, San Francisco, CA, 4The Feinstein Institute for Medical Research, New York, NY, 5University of California San Diego, San Diego, CA, 6Division of Nephrology, Ohio State University Medical Center, Columbus, OH, 7Pôle de pathologies rhumatismales systémiques et inflammatoires, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: lupus nephritis and outcome measures

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: 4M107 ACR Abstract: SLE–Clinical II: Renal & Neuropsychiatric Disease in SLE (1941–1945)

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Early endpoints predicting long-term outcome in lupus nephritis (LN), which could be used as outcome measures in clinical trials, are still debated. Recently, a multicentric study, using an extended international database of prospectively followed LN patients, succeeded in computing equations (hazard index; HI) predicting adverse kidney outcomes, in casu chronic kidney disease (CKD), severe kidney injury (SKI) and renal replacement therapy (RRT). These HI were validated in a replicate cohort. The HI for CKD, SKI and RRT (calculated with data measured at one year) were significantly higher in groups with long-term poor renal outcomes after a follow-up (FU) of ≥ 4 years (Mackay M et al. Arthritis Rheumatol 2016; 68 (suppl.10), abstract 967).

Objectives: To validate the HI for CKD, SKI and RRT in an independent LN cohort followed for ≥ 4 years and to check their validity to predict outcome in patients followed for ≥ 9 years.

Methods: Data from 229 consecutive LN patients followed in a single lupus center were screened. Only those for whom clinical data were available following their first episode of proliferative and/or membranous biopsy-confirmed LN were selected. Serum creatinine and proteinuria at different time points from 102 LN patients followed for ≥ 4 years were analyzed. At last FU, patients were divided according to the presence or absence of CKD, SKI and RRT. Their respective HI, measured at one year, were compared. CKD/SKI were defined as ≥ 30%/≥ 50% decrease in eGFR (CKD-EPI equation), compared to the highest value measured within the first year.

Results: As illustrated in the Table, the mean HI for CKD and SKI, measured at one year, were significantly higher in the groups of patients who indeed developed CKD and SKI after a FU of ≥ 4 years compared to those who did not. Importantly, the HI predictive value remained valid after a FU of ≥ 9 years. The mean HI for RRT was higher in patients who developed RRT after ≥ 4 and ≥ 9 years, but the difference was not statistically significant (p=0.08 and p=0.25, respectively), most likely due to the small numbers of RRT in this series. Of note, clinical (gender, age, mean serum creatinine, mean proteinuria) and pathological (ISN/RPS class) characteristics did not differ at baseline between patients with poor long-term renal outcome compared to the others.

Conclusion: We confirm the validity of the HI equations as early predictors of poor renal outcomes (CKD and SKI after long-term FU). These HI tools could be used as outcome measures in LN clinical trials.

Renal outcome ≥ 4 years

(102)

HI at one year

(mean ± SD)

Renal outcome ≥ 9 years

(76)

HI at one year

(mean ± SD)

Presence of CKD (21)

Absence of CKD (81)

0.69 ± 0.53*

0.30 ± 0.40

Presence of CKD (18)

Absence of CKD (58)

0.56 ± 0.63**

0.32 ± 0.36

Presence of SKI (8)

Absence of SKI (94)

-0.67 ± 0.36*

-1.20 ± 0.47

Presence of SKI (9)

Absence of SKI (67)

-0.72 ± 0.44*

-1.22 ± 0.45

Presence of RRT (5)

Absence of RRT (97)

-1.74 ± 0.74

-2.33 ± 0.74

Presence of RRT (6)

Absence of RRT (70)

-1.87 ± 0.74

-2.28 ± 0.70

HI : hazard index; figures between brackets correspond to numbers of patients; CKD : chronic kidney disease; SKI : severe kidney injury; RRT : renal replacement therapy; *: p<0.005; **: p<0.05 (Mann-Whitney U-tests).


Disclosure: F. Tamirou, None; M. Mackay, None; M. Dall'Era, None; J. Fishbein, None; K. C. Kalunian, None; B. H. Rovin, None; F. A. Houssiau, None.

To cite this abstract in AMA style:

Tamirou F, Mackay M, Dall'Era M, Fishbein J, Kalunian KC, Rovin BH, Houssiau FA. Early Prediction of Long-Term Renal Outcomes in Lupus Nephritis Using Hazard Index Equations [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/early-prediction-of-long-term-renal-outcomes-in-lupus-nephritis-using-hazard-index-equations/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/early-prediction-of-long-term-renal-outcomes-in-lupus-nephritis-using-hazard-index-equations/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology